Metachronous PDAC after breast cancer is a rare but serious occurrence, typically linked to hereditary predisposition syndromes involving pathogenic variants in homologous recombination repair (HRR) genes such as BRCA2, PALB2, and ATM (3–5). Here, BRCA2 is linked to breast cancer.